TICKERNERD
Menu
TMDXTMDXHealthcare · Medical Devices

TMDX Stock Forecast: TransMedics Group, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$89
−1.18% on the day

The 12 Wall Street analysts covering TransMedics Group, Inc. hold a median 12-month price target of $98 — +10.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 13 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.0B
Ticker Nerd rank
29 / 100
Median analyst target
$98
Analysts covering
12
Total return, dividends reinvested
1W
+5.6%
1M
+18.8%
YTD
−27.2%
1Y
−31.7%
From 52W high
−41.1%
From 52W low
+42.8%
$62
$150
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TMDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TransMedics Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
84
Value
70
Growth
63
Volatility
46
Revisions
39
Size
31
Momentum
25
Accruals
19
Issuance
18

Quality (84): The business earns solid, repeatable profits on what it owns.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TMDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26TMDXHigh $125Median $98Low $65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
8 Buy4 Hold0 Sell
Low $65Median $98High $125

The green dot is the last close — the median target sits +10.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Piper SandlerReiteratesOverweight$120 → $100
5 Aug 2026UBSMaintainsNeutral$80 → $77
3 Aug 2026NeedhamMaintainsBuy$142 → $106
28 July 2026UBSInitiatesNeutral—
6 July 2026Evercore ISI GroupMaintainsOutperform$100 → $90
6 July 2026Evercore ISI GroupMaintainsOutperform—
1 July 2026TD CowenReiteratesBuy$120
1 July 2026TD CowenReiteratesBuy—
30 June 2026Canaccord GenuityMaintainsBuy$124
30 June 2026Canaccord GenuityMaintainsBuy—
18 June 2026StifelMaintainsHold—
26 May 2026StifelMaintainsHold—
6 May 2026Canaccord GenuityMaintainsBuy—
6 May 2026NeedhamMaintainsBuy—
6 May 2026Piper SandlerMaintainsOverweight—
6 May 2026StifelMaintainsHold—
6 May 2026TD CowenMaintainsBuy—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
9 Mar 2026StifelMaintainsHold—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TMDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−26.2%
Analysts raising
0
Analysts cutting
5
Fundamentals

TransMedics Group, Inc. (TMDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.1×

Cheaper than 34% of US stocks

Price / sales
4.5×

Cheaper than 28% of US stocks

Price / book
5.8×

Cheaper than 19% of US stocks

EV / EBITDA
30.2×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
20.7%

Higher than 71% of US stocks

Earnings growth (YoY)
−57.9%

Higher than 8% of US stocks

Gross margin
59.6%

Higher than 73% of US stocks

Operating margin
12.5%

Higher than 68% of US stocks

Net margin
22.7%

Higher than 84% of US stocks

Returns & dividend
Return on equity
36.3%

Higher than 90% of US stocks

Return on assets
4.3%

Higher than 73% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TMDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TMDXTransMedics Group, Inc.$3.0B
29
NEOGNeogen Corp.$2.6B
94
AXGNAxoGen, Inc.$2.6B
81
UFPTUFP Technologies, Inc.$2.5B
75
IRTCiRhythm Holdings, Inc.$4.0B
78
BFLYButterfly Network, Inc.$2.4B
72
HAEHaemonetics Corp.$4.2B
99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TransMedics Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TMDX news & analysis

TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

Zacks Investment Research · 5 Aug 2026negative

TransMedics reported Q2 results with a revenue beat and a raised outlook, but the earnings missed expectations, with declining margins and sharply higher operating costs. The company's stock dipped following the report.

Why it matters — A TMDX watcher would care because the quarter highlights a contrast between stronger revenue and raised guidance versus margin compression and rising costs that weighed on profitability.

Why TransMedics Stock Is Sinking Today

The Motley Fool · 5 Aug 2026negative

TransMedics shares are falling after the company reported 21% sales growth but saw adjusted net income more than halved as it reinvested in growth. Sales growth may have decelerated, though the company's long-term vision is described as remaining intriguing.

Why it matters — A TMDX watcher would care because the company is trading near-term profitability for reinvestment in expansion, a key factor in assessing its earnings trajectory despite slower sales growth.

TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of TransMedics Group's Q2 2026 earnings call. The excerpt contains no details on the company's quarterly results or commentary from management.

Why it matters — A TMDX watcher would look to the earnings call transcript for management's discussion of quarterly performance and business outlook.

TransMedics Group Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

TransMedics Group reported record second-quarter revenue, driven by growth in liver procedures, clinical services, and transplant logistics. This growth was offset by increased spending on product development, international expansion, and infrastructure.

Why it matters — The record quarterly revenue indicates continued demand for TransMedics' transplant-related services even as the company invests heavily in expansion and development.

TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 5 Aug 2026neutral

TransMedics (TMDX) reported its financial results for the quarter ended June 2026. Zacks notes that while the headline earnings and revenue figures reflect the quarter's performance, the report also examines how key metrics compare with Wall Street estimates and year-ago values.

Why it matters — For TMDX watchers, the piece highlights the degree to which the company's quarterly metrics stacked up against analyst estimates and prior-year results.

FAQ

Frequently asked questions about TMDX stock

What is the TMDX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering TransMedics Group, Inc. have a median 12-month price target of $98, with estimates ranging from $65 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMDX stock a buy right now?

Of the 12 analysts covering TransMedics Group, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransMedics Group, Inc. 29 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMDX?

As at 13 Aug 2026, TransMedics Group, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (84 of 100).

Will TMDX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +10.1% from the last close, and Ticker Nerd's factor model ranks TransMedics Group, Inc. 29 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMDX stock forecast for 2030?

No analyst covering TransMedics Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $125 over the next 12 months.

How has TMDX stock performed over the past year?

TransMedics Group, Inc. returned -31.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TransMedics Group, Inc. do?

TransMedics Group Inc. is a commercial-stage medical technology company specializing in advanced systems and services for solid organ transplantation.

What is the latest news on TMDX?

The most recent item we track (Zacks Investment Research, 5 Aug 2026): "TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract". TransMedics reported Q2 results with a revenue beat and a raised outlook, but the earnings missed expectations, with declining margins and sharply higher operating costs. The company's stock dipped following the report.

Company

About TransMedics Group, Inc.

TransMedics Group Inc. is a commercial-stage medical technology company specializing in advanced systems and services for solid organ transplantation. Headquartered in Andover, Massachusetts, it focuses on improving the preservation, assessment, and transport of donor hearts, lungs, and livers for patients with end-stage organ failure. The company’s core platform, the Organ Care System, is a portable normothermic perfusion technology that keeps donor organs functioning in a near-physiologic state outside the body, enabling clinicians to evaluate and optimize organ quality prior to transplant. TransMedics combines this device platform with a service-led model that includes its National OCS Program, offering end-to-end organ retrieval, clinical management, logistics coordination, and dedicated transportation for transplant centers across the United States. Operating in the high-acuity transplant ecosystem, TransMedics plays a critical role in organ transplant workflows by helping transplant programs increase organ utilization and support complex heart, lung, and liver procedures through integrated technology and clinical services.

CEO Dr. Waleed H. Hassanein M.D. · 898 employees · United States · https://www.transmedics.com